注射用前列地尔与前列地尔注射液治疗早期慢性重型肝炎的比较

Alprostadil for injection vs alprostadil injection in treatment of early chronic severe hepatitis

目的 :观察注射用前列地尔 (PGE1 CD)与前列地尔注射液 (Lipo PEG1)治疗早期慢性重型肝炎的疗效与安全性。方法 :14 3例早期慢性重型肝炎的病人分 3组 ,3组病人均予相同的基础治疗。Lipo PGE1组 5 0例 ,加用Lipo PGE12 0 μg +5 %葡萄糖注射液 4 0mL ,微泵静脉注射 ,qd×2 8d。PGE1 CD组 5 3例 ,加用PGE1 CD 0 .1mg +5 %葡萄糖注射液 5 0 0mL ,iv ,gtt ,qd× 2 8d。对照组 4 0例 ,仅予基础治疗。结果 :治疗总有效率Lipo PGE1组为 6 6 % ,PGE1 CD组为 5 6 % ,对照组为 35 %。Lipo PGE1组与对照组比较差异有非常显著意义(P <0 .0 1)。不良反应率Lipo PGE1组为 18% ,PGE1 CD组为 5 7% ,对照组为 0。 3组间比较差异有显著意义 (P <0 .0 5 )。结论 :PGE1 CD与Lipo PGE1治疗早期慢性重型肝炎安全而有效 ,而Lipo

AIM: To observe the efficency and safety of alprostadil for injection (PGE_1-CD) and alprostadil injection (Lipo-PGE_1) in the treatment of the early chronic severe hepatitis. METHODS: One hundred and forty-three patients with early chronic severe hepatitis were divided into three groups. The patients of the three groups were all treated with the same basic treatment. Lipo-PGE_1 group of 50 patients was treated with Lipo-PGE_1 20 μg+5 % glucose injection 40 mL, iv with microinfusion pump, qd for 28 d. PGE_1-CD group of 53 patients was treated with PGE_1-CD 0.1 mg+5 % glucose injection 500 mL, iv, gtt, qd for 28 d. The control group of 40 patients was treated by the basic treatment only. RESULTS: The total effective rate was 66% in the Lipo-PGE_1 group, 56 % in the PGE_1-CD group and (35 %) in control group, respectively. There was a significant difference between Lipo-PGE_1 group and control group (P<0.01). The adverse reaction rate was (18 %) in Lipo-PGE_1 group, 57 % in PGE_1-CD group and 0 in the control group, respectively. The differences among the three groups were significant (P<0.05). CONCLUSION: Lipo-PGE_1 and PGE_1-CD are both effective and safe in treatment of early chronic severe hepatitis. Lipo-PGE_1 has rare adverse reactions.